A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Inclusion Criteria: Stratum 1: 1. Currently participating in Novartis study CAMN107A2109 2. Written signed and dated informed consent prior to any study procedures being performed Stratum 2: 1. Male or female 2. \> 18 years 3. ECOG 0,1,2 4. ASL/ALT \<= 2.5 ULN or \<= 5.0 ULN 5. Alcaline Phosfatase \<= 2.5 ULN 6. Serum Bilirrubin \<= 1.5 ULN 7. Serum Creatinine \<= 1.5 ULN or creatinine clearance \>=50 ml/min / 24 hours 8. Serum Lipase \<= 1.5 ULN Exclusion Criteria: Stratum 1 and stratum 2: 1. Reduction of the cardiac function 2. Use of Coumadin 3. Other severe medical concurrent conditions 4. Treatment with medications that prolonged the QT interval. 5. Mayor surgery 15 days before the inclusion in the protocol 6. Pregnant women or lactation Other protocol-defined inclusion/exclusion criteria may apply